– USA, CA – Apexigen, Inc., a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson to its Board of Directors as Chair, succeeding Dr. Ken Fong.
Ms. Karson will also join the Board of Directors as Chair of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp.
About Meenu Karson
Meenu Karson is a recognized biopharmaceutical executive with a successful track record of strategic leadership, transaction execution, and accelerating value-generating milestones. Since 2021, she has served as President and CEO of a private, discovery-stage company focused on GPCR neurobiology for the development of medicines that address multiple neuroscience indications. Before this role, Ms. Karson served as President and CEO of Proteostasis Therapeutics, Inc., a clinical-stage company focused on cystic fibrosis. During her tenure at Proteostasis, Ms. Karson played a key role in creating value through clinical validation and strategic partnering, raising more than $300 million in crossover and public financings, including the company’s IPO. Before Proteostasis, she served as President and CEO at Allozyne Inc., a clinical-stage protein bioconjugation company, where she drove accelerated development of the platform technology and clinical pipeline and created strategic partnering opportunities. Other career appointments include Vice President of Business Development and Licensing at Novartis AG, where she was a key member in all licensing strategies, processes, and outcomes in Europe and emerging growth markets as well as global M&A, and Chief Business Officer of Bioxell S.p.A., where she led the development of all corporate and commercial strategy. Additionally, Ms. Karson currently serves as a Board Member for Vallon Pharmaceuticals, Fore Biotherapeutics, and Vasomune Therapeutics.
“I am thrilled to join Apexigen at such a key inflection point for the Company,” said Meenu Karson. “Apexigen has built an impressive portfolio of immuno-oncology assets, and I look forward to working alongside its esteemed leadership team to support the Company during its next phase of growth as a public company driving long-term value for shareholders.”
Ms. Karson received a Bachelor of Science degree in Pharmacology from the University of Toronto and a Master of Business Administration in Strategy and Finance from the Schulich School of Business at York University.
About Apexigen, Inc.
Apexigen is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that may harness the patient’s immune system to combat and eradicate cancer. Sotigalimab and Apexigen’s other programs were discovered using Apexigen’s proprietary APXiMAB™ antibody discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Multiple product candidates have been discovered using the APXiMAB platform, one of which is commercially available and the others are in clinical development, either internally by Apexigen or by its licensees.
For more information: https://www.apexigen.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
